Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Nova Mentis Life Science Corp. C.LIB

Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the cultivation of AAAA premium, small batch, terpene rich dominant cultivars cured to perfection.


CSE:LIB - Post by User

Comment by Interpolation2on Sep 09, 2017 4:36pm
37 Views
Post# 26675984

RE:RE:US Connection? Greenhouse conversation....

RE:RE:US Connection? Greenhouse conversation....Deal is dead and some to all fo the shareholder capital raised for the initial payment may be unrecoverble.  Per June financials ...

9. INVESTMENT IN GR8 On January 31, 2017, the Company entered into a letter of intent (“LOI”) to acquire up to a 27.5% interest in GR8 Track, Inc. (“GR8”), a private corporation based in California, USA, licensed to produce cannabis for medical use. Pursuant to the terms of the agreement, the Company paid a deposit of $50,000 USD within 7 business days from execution of the LOI.
The definitive agreement was subject to a 60-day due diligence period and the Company completing a minimum financing of $500,000 CAD gross proceeds. As of the date of the filing of this report, the due diligence period has expired and the Company’s Management has decided to no longer pursue the acquisition. Management believes the Company will recover some of the US$50,000 deposit paid. If necessary, Management will record an impairment loss during the year ended December 31, 2017 upon reaching a termination agreement.

rcash1 wrote: Go back and look over the Cali LOI soon to be definitely deal and do some dd. There medically licensed and potential for large growth via greenhouse space(future )  + revenue already ;)


Bullboard Posts